Clinical Trials
228
Active:9
Completed:194
Trial Phases
5 Phases
Phase 1:20
Phase 2:31
Phase 3:53
+2 more phases
Drug Approvals
103
FDA:66
NMPA:17
PPB:15
+1 more agencies
Drug Approvals
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- 国药准字HJ20160346
- Approval Date
- Nov 4, 2024
NMPA
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- 国药准字HJ20160348
- Approval Date
- Nov 4, 2024
NMPA
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- 国药准字HJ20160347
- Approval Date
- Nov 4, 2024
NMPA
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- 国药准字HJ20160349
- Approval Date
- Oct 29, 2024
NMPA
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- 国药准字HJ20160350
- Approval Date
- Oct 29, 2024
NMPA
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 氯替泼诺混悬滴眼液
- Approval Number
- 国药准字HJ20191002
- Approval Date
- May 11, 2023
NMPA
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 氯替泼诺混悬滴眼液
- Approval Number
- 国药准字HJ20180059
- Approval Date
- May 11, 2023
NMPA
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- H20160350
- Approval Date
- Jun 19, 2020
NMPA
Loteprednol Etabonate and Tobramycin Eye Drops
- Product Name
- 氯替泼诺妥布霉素滴眼液
- Approval Number
- H20160349
- Approval Date
- Jun 19, 2020
NMPA
Loteprednol Etabonate Ophthalmic Suspension
- Product Name
- 露达舒
- Approval Number
- H20160347
- Approval Date
- Jun 11, 2020
NMPA
- Prev
- 1
- 2
- Next
Clinical Trials
Distribution across different clinical trial phases (215 trials with phase data)• Click on a phase to view related trials
Not Applicable
88 (40.9%)Phase 3
53 (24.7%)Phase 2
31 (14.4%)Phase 4
23 (10.7%)Phase 1
20 (9.3%)Phase 2 Study of BL1107 Eye Drops vs. Timolol in Adults With Primary Open Angle Glaucoma or Ocular Hypertension
Not Applicable
Not yet recruiting
- Conditions
- Glaucoma
- Interventions
- First Posted Date
- 2025-09-11
- Last Posted Date
- 2025-09-11
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 228
- Registration Number
- NCT07168902
A Study Evaluating the Safety and Efficacy of a Fixed-Dose Combination for Dry Eye Disease
Not Applicable
Not yet recruiting
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Lifitegrast/Perfluorohexyloctane Fixed Dose CombinationDrug: Vehicle
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 423
- Registration Number
- NCT07128628
A Study to Assess the Long-Term Safety of Lifitegrast/Perfluorohexyloctane Fixed-Dose Combination in Subjects With Dry Eye Disease
Not Applicable
Not yet recruiting
- Conditions
- Dry Eye Disease
- Interventions
- Drug: Lifitegrast/perfluorohexyloctane (PFHO)
- First Posted Date
- 2025-08-08
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 150
- Registration Number
- NCT07111013
A Study to Evaluate Concomitant Perfluorohexyloctane Use With Contact Lens Wear
Not Applicable
Recruiting
- Conditions
- Dry Eye
- Interventions
- Drug: Perfluorohexyloctane ophthalmic solution
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 100
- Registration Number
- NCT07054606
- Locations
- 🇺🇸
Site 101, San Diego, California, United States
🇺🇸Site 105, San Francisco, California, United States
🇺🇸Site 107, Longwood, Florida, United States
A Study to Assess Safety, Tolerability, and Pharmacokinetics of Ascending Concentrations of Topical Ocular BL1332 in Healthy Volunteers
Phase 1
Not yet recruiting
- Conditions
- Ocular Pain
- Interventions
- Drug: BL1332 ophthalmic solutionDrug: BL1332 ophthalmic vehicle
- First Posted Date
- 2025-05-18
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Bausch & Lomb Incorporated
- Target Recruit Count
- 24
- Registration Number
- NCT06978244
- Locations
- 🇺🇸
Site 101, Fair Lawn, New Jersey, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 44
- Next
News
Lifitegrast Shows Long-Term Safety and Efficacy for Dry Eye Disease in 7-Year Analysis
A 7-year postmarketing analysis of lifitegrast ophthalmic solution 5% (Xiidra) confirms its favorable safety profile with no new safety signals identified across nearly 800,000 patient treatment years.
MIEBO Demonstrates Efficacy in Dry Eye Disease Treatment
MIEBO (perfluorohexyloctane ophthalmic solution) is FDA-approved for treating the signs and symptoms of dry eye disease (DED).